

# CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE QUARTER AND PERIOD ENDED 31 DECEMBER 2018 (UNAUDITED)

	Current Period 31 December		
$-\frac{31\mathrm{Dec}}{2018}$	2017		
	2017		
395,939	370,709		
) (293,240)	(272,510)		
102,699	98,199		
19,347	7,706		
) (10,344)	(9,176)		
(39,664)	(54,031)		
(7,864)	(8,710)		
64,174	33,988		
1,577	681		
5,991	5,021		
) (20,346)	(24,965)		
51,396	14,725		
) (20,631)	(17,374)		
30,765	(2,649)		
90,705	(2,015)		
_	42,467		
30,765	39,818		
30,703	39,010		
13,774	(4,505)		
5,590	18,578		
50,129	53,891		
25,706	(5,239)		
-	31,158		
25,706	25,919		
5,059	13,899		
30,765	39,818		
45,070	7,841		
	31,906		
45,070	39,747		
5,059	14,144		
50,129	53,891		
= ======			
) 15.33	(1.13)		
-	6.74		
15.33	5.61		
) 15.33	(1.13)		
-	6.74		
	5.61		
_	15.33		

The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the Notes to the Interim Financial Report.

# CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2018 (UNAUDITED)

In thousands of RM	As at 31 December 2018	As at 31 December 2017
ASSETS		
Property, plant and equipment	179,928	143,816
Investment properties	365	20,020
Intangible assets	94,107	94,170
Investment in associates	13,720	15,608
Other investments	186	45,568
Deferred tax as sets	1,355	2,321
Total non-current assets	289,661	321,503
Inventories	29,220	39,277
Current tax assets	12,596	18,330
Trade and other receivables	92,466	136,005
Cash and cash equivalents	136,295	160,345
	270,577	353,957
Assets classified as held for sale	19,800	185,900
Total current assets	290,377	539,857
TOTAL ASSETS	580,038	861,360
EQUITY AND LIABILITIES		
Share capital	81,920	81,920
Reserves	27,008	163,421
Retained earnings	211,221	36,923
Total equity attributable to equity holders of the Company	320,149	282,264
Non-controlling interests	3,699	(1,360)
Total equity	323,848	280,904
Loans and borrowings	152,107	108,750
Deferred tax liabilities	15,216	24,044
Total non-current liabilities	167,323	132,794
Loans and borrowings	41,695	359,388
Trade and other payables	46,320	87,980
Current tax liabilities	852	294
Total current liabilities	88,867	447,662
Total liabilities	256,190	580,456
TOTAL EQUITY AND LIABILITIES	580,038	861,360
Net assets per share attributable to ordinary equity holders of the parent (sen)	191	168

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Notes to the Interim Financial Report.

## CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 31 DECEMBER 2018 (UNAUDITED)

In thousands of RM	<b>∢</b> -	Attributable to s hareholders of the Company  Non-distributable Distribut-				<b>→</b>						
	Share capital	Share premium	Capital redemption	Translation reserve	Fair value reserve	Revalua- tion reserve	Other capital reserve	Treasury shares	able Retained earnings	Total	Non- controlling interest	Total equity
At 1 January 2018 (restated)	81,920	-	-	18,351	29,727	112,361	2,982	-	34,769	280,110	(1,360)	278,750
Changes in fair value of												
equity investment at FVOCI	-	-	-	-	13,774	-	-	-	-	13,774	-	13,774
Foreign curency translation differences	_	_	_	5,590	_	_	_	_	_	5,590	_	5,590
Realisation of revaluation				3,370						3,370		3,370
reserves upon disposal of												
property	-	-	-	-	-	(112,361)	-	-	112,361	-	-	-
Total other comprehensive												
income for the period	-	-	-	5,590	13,774	(112,361)	-	-	112,361	19,364	-	19,364
Profit for the period	-	-	-	-	-	-	-	-	25,706	25,706	5,059	30,765
Total comprehensive income				5.500	12.774	(110.261)			120.07	45.070	5.050	50.120
for the period Transfer of gain on disposal	-	-	-	5,590	13,774	(112,361)	-	-	138,067	45,070	5,059	50,129
of equity investment at												
FVOCI to retained earnings	_	_	_	_	(43,416)	_	_	_	43,416	_	_	_
Dividends to owners					, , ,				,			
of the Company	-	-	-	-	-	-	-	-	(5,031)	(5,031)	-	(5,031)
As at end of period	81,920	-	-	23,941	85	-	2,982	-	211,221	320,149	3,699	323,848

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Notes to the Interim Financial Reports.

## CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 31 DECEMBER 2017

In thousands of RM	4			utable to shar	eholders of	the Compan	y ——		——► Distribut-			
	Share capital	Share premium	Capital redemption	Translation reserve	Fair value reserve	Revalua- tion reserve	Other capital reserve	Treasury shares	able Retained earnings	Total	Non- controlling interest	Total equity
At 1 January 2017	457,630	39,944	73	(228)	34,233	112,361	2,982	(5,836)	98,429	739,588	152,188	891,776
Fair value of available-for-sale financial assets Foreign currency translation	-	-	-	-	(4,506)	-	-	-	-	(4,506)	-	(4,506)
differences	_	_	_	18,579	_	_	_	_	_	18,579		18,579
Total other comprehensive				,								10,017
income for the period	-	-	-	18,579	(4,506)	-	-	-	-	14,073	-	14,073
Profit for the year	-	-	-	-	-	-	-	-	25,919	25,919	13,899	39,818
Total comprehensive income for the period  Dividends to owners	-	-	-	18,579	(4,506)	-	-	-	25,919	39,992	13,899	53,891
of the Company Dividends to non-controlling	-	-	-	-	-	-	-	-	(11,366)	(11,366)	-	(11,366)
interests	-	-	-	-	-	-	-	-	-	-	(8,403)	(8,403)
Treasury shares sold	-	-	-	-	-	-	-	5,836	(1,277)	4,559	-	4,559
Acquisition of non-controlling interests	-	-	-	-	-	-	-	-	(8,834)	(8,834)	(31,166)	(40,000)
Placement of new shares	60,010	-	-	-	-	-	-	-	-	60,010	-	60,010
Effect of demerger	(475,737)	-	-	-	-	-	-	-	(65,948)	(541,685)	(127,878)	(669,563)
Trans fer in accordance with Section 618(2) of the												
Companies Act 2016	40,017	(39,944)	(73)	-	-	-	-	-	-	-	-	_
As at 31 December 2017	81,920	-	-	18,351	29,727	112,361	2,982	-	36,923	282,264	(1,360)	280,904

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Notes to the Interim Financial Reports.

# CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 31 DECEMBER 2018 (UNAUDITED)

## 12 Months Ended 31 December

	12 Mondis Ended 3	of December
In thousands of RM	2018	2017
Cash flows from operating activities		
Profit before taxation		
- continuing operations	51,396	14,725
- discontinued operation	-	51,779
•	51,396	66,504
Adjustments for:		
Change in fair value of investment properties	(220)	(200)
Depreciation of property, plant and equipment	22,863	46,763
Net (gain)/loss on disposal of property	(4,100)	190
Finance costs	20,346	30,229
Interest income	(5,991)	(7,735)
Impairment loss on receivables	(2,205)	(1,144)
Impairment loss on intangibles	63	1,769
Impairment loss on property, plant and equipment	-	185
Provision for obsolete stock	914	(2,464)
Share of profit of equity accounted associates	(1,577)	(681)
Provision for warranty	-	203
Inventories written down / written off	854	5,924
Properites, pant and equipment written off	180	58
Unrealised foreign exchange loss/(gain)	645	(2,004)
Operating profit before changes in working capital	83,168	137,597
Change in inventories	8,289	(5,946)
Change in payables and accruals	(41,170)	38,864
Change in receivables, deposits and prepayments	42,447	(47,235)
Cash generated from operations	92,734	123,280
Finance costs paid	(20,346)	(30,229)
Interest income	5,991	7,735
Income tax paid	(20,074)	(24,312)
Net cash generated from operating activities	58,305	76,474
Cash flows from investing activities		
Acquisition of property, plant and equipment	(52,188)	(88,059)
Acquisition of development expenditure	-	(5,277)
Acquisition of non-controlling interests	_	(40,000)
Proceeds from disposal of other investments	59,157	-
Proceeds from disposal of property, plant and equipment	190,000	118
Net cash outflow from demerger of subsidiary	-	(96,020)
Net cash generated/(used in) investing activities	196,969	(229,238)
Cash flows from financing activities		(==>,===)
Dividends paid to owners of the Company	(5,031)	(11,366)
Dividends paid to non-controlling interests	-	(8,403)
Proceeds from sale of treasury shares	_	4,559
Proceeds from new share issued	_	60,010
Net repayment of loans and borrowings	(274,336)	(26,174)
Net cash (used in)/generated from financing activities	(279,367)	18,626
Exchange difference on translation of the	(277,887)	10,020
financial statements of foreign operations	43	6,166
Net decrease in cash and cash equivalents	(24,050)	(127,972)
Cash and cash equivalents at 1 January	160,345	288,317
Cash and cash equivalents as at end of period	136,295	160,345
The same of the same as at one of period	130,275	100,5 15

The Condensed Cash Flow Statement should be read in conjunction with the Notes to the Interim Financial Report.



# CHEMICAL COMPANY OF MALAYSIA BERHAD (5136-T) (Incorporated in Malaysia) For the Period Ended 31 December 2018

## NOTES TO THE INTERIM FINANCIAL REPORT

#### A1) Basis of preparation

The interim financial report is unaudited and has been prepared in accordance with the applicable disclosure provisions of the Listing Requirements of the Bursa Malaysia Securities Berhad and MFRS 134, *Interim Financial Reporting* in Malaysia. They do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 December 2017.

## **A2)** Changes in Accounting Policies

The accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted in the audited financial statements for the financial year ended 31 December 2017 except for those standards, amendments and interpretations which are effective from the annual period beginning on or after 1 January 2018.

## MFRSs, Interpretations and Amendments effective for annual periods beginning on or after 1 January 2018;

- MFRS 9, Financial Instruments (2014)
- MFRS 15, Revenue from Contracts with Customers
- Clarifications to MFRS 15, Revenue from Contracts with Customers
- IC Interpretation 22, Foreign Currency Transactions and Advance Consideration
- Amendments to MFRS 1, First-time Adoption of Malaysian Financial Reporting Standards (Annual Improvements 2014-2016 Cycle)
- Amendments to MFRS 2, Share-based Payment Classification and Measurement of Share-based Payment Transactions
- Amendments to MFRS 4, Insurance Contracts Applying MFRS 9- Financial Instruments with MFRS 4-Insurance Contracts
- Amendments to MFRS 128, *Investments in Associates and Joint Ventures (Annual Improvements 2014-2016 Cycle)*
- Amendments to MFRS 140, Investment Property Transfer of Investment Property

The Group adopted the above MFRSs and Amendments to MFRSs except for MFRS 2 and MFRS 4 which are not applicable to the Group. The initial application of the accounting standards, amendments or interpretations are not expected to have any material financial impacts to the current period and prior period financial statements of the Group and the Company except as mentioned below:

## (i) MFRS 15, Revenue from Contracts with Customers

MFRS 15 replaces the guidance in MFRS 111, Construction Contracts, MFRS 118, Revenue, IC Interpretation 13, Customer Loyalty Programmes, IC Interpretation 15, Agreements for Construction of Real Estate, IC Interpretation 18, Transfers of Assets from Customers and IC Interpretation 131, Revenue - Barter Transactions Involving Advertising Services.

Previously, the Group recognised revenue from contracts with customers on the basis of the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates. Upon adoption of MFRS 15, the Group recognises the revenue from contracts with customers that require customer-related costs to be allocated as a deduction of revenue.



# CHEMICAL COMPANY OF MALAYSIA BERHAD (5136-T) (Incorporated in Malaysia) For the Period Ended 31 December 2018

### A2) Changes in Accounting Policies

### MFRS 15, Revenue from Contracts with Customers (continued)

The Group manufactures and sells certain chemical products for a customer under a non-cancellable exclusive rights to supply contract. Previously, the Group recognised revenue from contracts with customers after the significant risk and rewards of ownership is transferred to the customers. Upon adoption of MFRS 15, the Group recognises the revenue from contracts with customers when the performance obligations are satisfied over time. The Group applies MFRS 15 retrospectively with the cumulative effect of initially applying this Standard recognised at the date of initial application.

### (ii) MFRS 9, Financial instruments

MFRS 9 replaces the guidance in MFRS 139, *Financial Instruments: Recognition and Measurement* on the classification and measurement of financial assets and financial liabilities, impairment of financial assets, and on hedge accounting.

MFRS 9 contains a new classification and measurement approach for financial assets that reflects the business model in which assets are managed and their cash flow characteristics. The new standard contains three principle classification categories for financial assets: measured at amortised cost, fair value through other comprehensive income (FVOCI) and fair value through profit or loss (FVTPL), and eliminates the existing MFRS 139 categories of held to maturity, loans and receivables and available for sale. Upon adoption of MFRS 9, financial assets previously measured at available for sale is now measured using FVOCI.

The following revised MFRSs and Amendments to MFRSs have been issued by the MASB and are not yet effective for adoption by the Group:

## MFRSs, Interpretations and Amendments effective for annual periods beginning on or after 1 January 2019;

- MFRS 16, Leases
- IC Interpretation 23, Uncertainty over Income Tax Treatments
- Amendments to MFRS 3, Business Combinations Previously Held Interest in a Joint Operation (Annual Improvements to MFRS Standards 2015–2017 Cycle)
- Amendments to MFRS 9, Financial Instruments Prepayment Features with Negative Compensation
- Amendments to MFRS 11, Joint Arrangements Previously Held Interest in a Joint Operation (Annual Improvements to MFRS Standards 2015–2017 Cycle)
- Amendments to MFRS 112, Income Taxes Income Tax Consequences of Payments on Financial Instruments Classified as Equity (Annual Improvements to MFRS Standards 2015–2017 Cycle)
- Amendments to MFRS 123, Borrowing Costs Borrowing Costs Eligible for Capitalisation (Annual Improvements to MFRS Standards 2015–2017 Cycle)
- Amendments to MFRS 128, Investment in Associates and Joint Ventures Long-term Interests in Associates and Joint Ventures
- Plan Amendment, Curtailment or Settlement (Amendments to MFRS 119 Employee Benefits)



(Incorporated in Malaysia)

For the Period Ended 31 December 2018

### A2) Changes in Accounting Policies (continued)

## MFRSs, Interpretations and Amendments effective for annual periods beginning on or after 1 January 2020;

- Amendments to MFRS 2, Share-Based Payment
- Amendment to MFRS 3, Business Combinations
- Amendments to MFRS 6, Exploration for and Evaluation of Mineral Resources
- Amendment to MFRS 14, Regulatory Deferral Accounts
- Amendments to MFRS 101, Presentation of Financial Statements
- Amendments to MFRS 108, Accounting Policies, Changes in Accounting Estimates and Errors
- Amendments to MFRS 134, Interim Financial Reporting
- Amendment to MFRS 137, Provisions, Contingent Liabilities and Contingent Assets
- Amendment to MFRS 138, Intangible Assets
- Amendment to IC Interpretation 12, Service Concession Arrangements
- Amendment to IC Interpretation 19, Extinguishing Financial Liabilities with Equity Instruments
- Amendment to IC Interpretation 20, Stripping Costs in the Production Phase of a Surface Mine
- Amendment to IC Interpretation 22, Foreign Currency Transactions and Advance Consideration
- Amendments to IC Interpretation 132, Intangible Assets-Web Site Costs
- Amendments to MFRS 3, Business Combination Definition of a Business
- Amendments to MFRS 101, Presentation of Financial Statements and MFRS 108, Accounting Policies, Changes in Accounting Estimates and Errors Definition of Material

## MFRSs, Interpretations and Amendments effective for annual periods beginning on or after 1 January 2021;

• MFRS 17, Insurance Contracts

## MFRSs, Interpretations and Amendments effective for annual periods beginning on or after a date yet to be confirmed;

 Amendments to MFRS 10, Consolidated Financial Statements and MFRS 128, Investments in Associates and Joint Ventures – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture.

The Group do not plan to adopt the above MFRS 11 and MFRS 17 which are not applicable for the Group. The initial applications of the above standards are not expected to have any material financial impacts.

## A3) Disclosure of audit report qualification

The auditor's report on the financial statements of the Group and the Company for the year ended 31 December 2017 was not subject to any qualification.

### A4) Explanatory comments about the seasonality or cyclicality of operations

The Group's operations were not subjected to any material seasonal or cyclical factor other than market fluctuations in selling prices and costs of raw materials.



(Incorporated in Malaysia)

For the Period Ended 31 December 2018

#### A5) Unusual items due to their nature, size or incidence

There was no item affecting assets, liabilities, net income or cash flows that were unusual because of their nature, size or incidence for the current quarter and financial period under review.

## A6) Changes in prior estimates of amounts which materially affect the current interim period

There were no material changes in prior year estimates which would materially affect the current interim period.

## A7) Issuances, cancellations, repurchases, resale and repayments of debt and equity securities

There was no issuance, cancellation, repurchase, resale and repayment of debt and equity securities during the period under review.

## A8) Dividends paid

On 29 June 2018, the Company paid first interim single tier dividend of 3.00 sen per ordinary share totalling RM5.0 million for the financial year ending 31 December 2018.

## A9) Segment reporting

	Segment Revenue						
In thousands of RM	Individual 4t	h Quarter	Cumulative 4th Quarter				
	2018	2017	2018	2017			
Continuing operations							
Chemicals	77,750	85,727	305,383	283,565			
Polymers	24,026	23,556	94,324	84,277			
Others* and inter-segment transactions	(1,317)	(51)	(3,768)	2,867			
Group result	100,459	109,232	395,939	370,709			
<b>Discontinued operations</b>							
Pharmaceuticals	-	112,253	-	467,987			
•	100,459	221,485	395,939	838,696			

<sup>\*</sup> Administrative and non-core activities

Segment Profit/(Loss) Before Tax

In thousands of RM	Individual 4tl	n Quarter	Cumulative 4th Quarter				
	2018	2017	2018	2017			
Continuing operations							
Chemicals	13,068	16,706	51,196	44,029			
Polymers	3,499	4,296	18,744	18,765			
Others* and inter-segment transactions	(6,946)	(14,177)	(18,544)	(48,069)			
Group result	9,621	6,825	51,396	14,725			
<u>Discontinued operations</u>							
Pharmaceuticals	-	12,808	-	51,779			
	9,621	19,633	51,396	66,504			

<sup>\*</sup> Administrative and non-core activities



For the Period Ended 31 December 2018

### A10) Revaluation of property, plant and equipment

The Group adopts the cost model for its property, land and building.

#### A11) Post balance sheet events

There are no material events after the period end that had not been reflected in the Interim Financial Reports for the current financial period under review.

## A12) Changes in the composition of the Group

There were no material changes in the composition of the Group for the period under review.

## A13) Changes in contingent liabilities or contingent assets since the last annual balance sheet date

During the financial year 2014, PT CCM Indonesia ("PTCCMI"), a subsidiary of the Company appealed against tax auditor's assessment with respect to year of assessment 2011. The contingent liability involved in the tax appeal was IDR34.3 billion (equivalent to approximately RM9.85 million).

On 13 December 2018, PT CCMI received the official notification on the judgement in favour of its appeals to the Tax Court of Indonesia. These successful appeals relate to several tax adjustments/ corrections made by the tax auditor amounting to IDR34.06 billion (equivalent to approximately RM9.78 million) representing 99.25% of the total appealed amount.

Save as disclosed, there are no changes in contingent liabilities or assets as at the end of the current interim financial period.

#### A14) Capital Commitments

	31	31
	December	December
	2018	2017
	RM'000	RM'000
Contracted but not provided for	5,526	22,249

## A15) Discontinued operations and assets/liabilities classified as Held for Sale

- (i) In 2017, the Company distributed its entire shareholding in CCM Duopharma Biotech Berhad ("CCMD") to the shareholders of the Company. Following the distribution, CCMD has ceased to be a subsidiary of the Company, thus reported as Discontinued Operation results, in the comparative period of 2017.
- (ii) In 2017, the Company entered into a Sale and Purchase Agreement for disposal of three (3) parcels of leasehold land measuring approximately 70.93 acres for a cash consideration of RM190 million to Global Vision Logistics Sdn Bhd, thus reclassified as Asset Held For Sale. The disposal was completed on 13 June 2018.
- (iii) On 7 September 2018, the Company entered into a Sale and Purchase Agreement with Rock Link Sdn Bhd to dispose of a piece of land in Mukim of Labu, District of Seremban, Negeri Sembilan for a cash consideration of RM21.5 million, thus reclassified as Asset Held For Sale.



(Incorporated in Malaysia)

For the Period Ended 31 December 2018

## A15) Discontinued operations and assets/liabilities classified as Held for Sale (continued)

The results of the discontinued operations were as follows:-

	Current	Current Period		
In thousands of RM	12 months ended 3	1 December		
	2018	2017		
Results of discontinued operation				
Revenue	-	467,987		
Expenses		(416,208)		
Results from operating activities	-	51,779		
Income tax expense	-	(9,312)		
Profit from discontinued operations	-	42,467		
Cash flows of discontinued operation				
Cash generated from operating activities	-	37,921		
Cash used in investing activities	-	(71,875)		
Cash used in financing activities	-	14,143		
Effect of cash flows		(19,811)		
Assets Held for Sale as at end of the period consists of:-				
	As at	As at		
In thousands of RM	31 December 2018	31 December 2017		
Assets classified as held for sale				
Investment property	19,800	185,900		
	19,800	185,900		



For the Period Ended 31 December 2018

## Explanatory Notes Pursuant to Appendix 9B of the Listing Requirements of Bursa Malaysia Securities Berhad

#### **B1**) **Review of Performance**

## Commentary for Individual Quarter ended 31 December 2018

## Continuing operations

In thousands of RM	Current Year Quarter	Preceding Year Corres-ponding Quarter	Changes (Amount)	Changes (%)
Segment Revenue				` '
Chemicals	77,750	85,727	(7,977)	(9.3)
Polymers	24,026	23,556	470	2.0
Others and inter-segment transactions	(1,317)	(51)	(1,266)	>100.0
Group result (continuing operations)	100,459	109,232	(8,773)	(8.0)
Segment profit/(loss) before tax				
Chemicals	13,068	16,706	(3,638)	(21.8)
Polymers	3,499	4,296	(797)	(18.6)
Others and inter-segment transactions	(6,946)	(14,177)	7,231	(51.0)
Group result (continuing operations)	9,621	6,825	2,796	41.0

The Group recorded profit before tax in the current quarter of RM9.6 million, increased from RM6.8 million recorded in the same quarter last year, in spite of achieving lower revenue. The improvement in profit before tax was contributed by the savings in finance cost of RM2.6 million pursuant to the Group's continuous de-gearing exercise undertaken throughout the quarter. The preceding year's profit before tax has taken into account the voluntary separation scheme cost amounting to RM5.5 million.

Chemicals Division has recorded a lower revenue and profit before tax by 9.3% and 21.8% respectively during the current quarter primarily due to lower average selling prices of its chlor-alkali products on the back of fluctuation in chemical commodity prices.

Polymers Division's profit before tax for the current quarter decreased from RM4.2 million to RM3.5 million due to write-off of assets not in use, on the back of revenue growth of 2%.

## Discontinued operation

On 28 December 2017, the Company distributed its entire shareholding in CCM Duopharma Biotech Berhad ("CCMD") to the shareholders of the Company. Following the distribution, CCMD has ceased to be a subsidiary of the Company, thus reported as Discontinued Operation results as comparative in 2017. During the fourth quarter of 2017, the Pharmaceuticals Division recorded revenue of RM112.3 million and profit before tax of RM12.8 million.



For the Period Ended 31 December 2018

## Commentary for Cumulative Quarter ended 31 December 2018

#### Continuing operations

In thousands of RM	Current Year To Date	Preceding Year Corres-ponding Period	Changes (Amount)	Changes (%)
Segment Revenue				
Chemicals	305,383	283,565	21,818	7.7
Polymers	94,324	84,277	10,047	11.9
Others and inter-segment transactions	(3,768)	2,867	(6,635)	>100.0
Group result (continuing operations)	395,939	370,709	25,230	6.8
Segment profit/(loss) before tax				
Chemicals	51,196	44,029	7,167	16.3
Polymers	18,744	18,765	(21)	(0.1)
Others and inter-segment transactions	(18,544)	(48,069)	29,525	(61.4)
Group result (continuing operations)	51,396	14,725	36,671	249.0

For the current period ended 31 December 2018, the Group recorded profit before tax of RM51.4 million compared to RM14.7 million in the corresponding period last year with the revenue growth of 6.8%. During the period under review, both businesses recorded resilient performance and improved margins from their business operations. Further, the improved performance was also contributed by the following factors:

- Savings of the Group's finance cost of RM4.6 million or 18% reduction compared to the last year pursuant to the Group's continuous de-gearing exercise which was undertaken throughout the year. The proceeds from the divestment of its 2 non-core assets namely disposal of its 8.39% equity interest in PanGen Biotech Inc. and disposal of Shah Alam land amounting to RM249.2 million was used to pare down its borrowings.
- The disposal of Shah Alam land which was completed in June 2018 has resulted in gain of RM4.1 million.
- The profit before tax for the period ended 31 December 2017 also took into account RM7.0 million incurred for the corporate exercises which led to leaner corporate office setup and operational efficiency.

Chemicals Division recorded a higher profit before tax of RM51.2 million, as compared to RM44.0 million in 2017 on the back of 7.7% increase in revenue. The increase in revenue and profit before tax were primarily the result of higher average selling prices of its chlor-alkali products as well as higher volume sold during the period under review. This was further supported by improvement in its manufacturing efficiency and other cost control initiatives.

Polymers Division's profit before tax for the current period stabilised at RM18.7 million with growth in revenue of 11.9%.



For the Period Ended 31 December 2018

## **Commentary for Cumulative Quarter ended 31 December 2018 (continued)**

## **Discontinued operation**

On 28 December 2017, the Company distributed its entire shareholding in CCM Duopharma Biotech Berhad ("CCMD") to the shareholders of the Company. Following the distribution, CCMD has ceased to be a subsidiary of the Company, thus reported as Discontinued Operation results as comparative in 2017. Pharmaceuticals Division recorded revenue of RM468.0 million and profit before tax of RM51.8 million for the year 2017.

## B2) Material Changes in the Quarterly Results Compared to the Results of the Preceding Quarter

### Continuing operations

In thousands of RM	Current Quarter	Preceding Quarter	Changes (Amount)	Changes (%)
Segment Revenue				
Chemicals	77,750	71,795	5,955	8.3
Polymers	24,026	24,129	(103)	(0.4)
Others and inter-segment transactions	(1,317)	(856)	(461)	53.9
Group result	100,459	95,068	5,391	5.7
Segment profit/(loss) before tax		_		
Chemicals	13,068	11,947	1,121	9.4
Polymers	3,499	4,906	(1,407)	(28.7)
Others and inter-segment transactions	(6,946)	(5,971)	(975)	16.3
Group result	9,621	10,882	(1,261)	(11.6)

The Group's revenue for the current quarter of RM100.5 million was higher by 5.7% as compared to the preceding quarter revenue of RM95.1 million. The higher revenue was mainly contributed by higher sales volume recorded by Chemical Divisions during the quarter. Group's profit before tax for the current quarter decreased slightly to RM9.6 million compared to RM10.9 million in the preceding quarter due to write-off of assets not in use.

## **B3**) Prospects

During the period under review, the Group has completed two (2) major divestments of its non-core assets which has raised a total proceed of RM249.2 million that was used to pare down its borrowing and thus strengthening its gearing position from 1.67 times in 2017 to 0.60 times as at end of 2018. The continuous de-gearing exercise has also contributed to reduction in finance cost by 18% compared to 2017. With the stronger financial position, the Group is now able to pursue its expansion and growth strategies.

In line with its strategic plan, the Group is focusing its effort in expanding its two (2) core businesses, Chemicals and Polymers Divisions. Both businesses will pursue new opportunities within their respective markets to increase their market share in order to ensure sustainable growth.



For the Period Ended 31 December 2018

#### **B3)** Prospects (continued)

On Chemicals Division, the reactivation of Pasir Gudang Plant 1 (PGW1) is set to be completed by the second half of this year. This effort will increase the total chlor-alkali production capacity by 50 per cent annually once it begins operations. This will allow the Division to seize the existing market opportunities for its chlor-alkali products. In addition, Chemicals Division will continue with various improvement programs to gain benefit from operational savings. The Division will also continue to grow its core capabilities both domestically and regionally in order to strengthen its market share. However, the Division remains cautious of the fluctuation in chemical commodity prices, which may variably give an impact to the results.

Polymer Division's performance is expected to grow steadily in tandem with the growth of the global demand for gloves. Based on the forecast by Malaysian Rubber Glove Manufacturers Association (MARGMA), the demand for gloves is expected to grow 8% - 10% per annum over the next two years. However, the Division expects the business environment to be challenging in the coming year, in view of intensifying competition and cost increases. In order to stay ahead of the competition, the Division is strengthening its product development capabilities and undertaking capacity expansion. Ongoing efforts are also in place to improve production process including leveraging on automation with the objective of enhancing cost efficiency and quality improvement.

### **B4)** Variance of Actual Profit from Forecast Profit

The Group did not make any profit forecast or issue any profit guarantee.

#### **B5**) Taxation

Taxation charge of the Group for the current quarter and the financial period was as follows:

	Current Quarter	Current Period
Taxation	RM'000	RM'000
In respect of profit for the period	3,031	18,945
Real Property Gains Tax (RPGT)	-	9,548
Transfer from deferred tax	(3,167)	(7,862)
	(136)	20,631

The Group's effective tax rate was higher than the statutory tax rate mainly due to the RPGT incurred during the quarter on the Disposal of Shah Alam Land and non-deductibility of certain expenses for tax purposes.

#### **B6)** Profit before Tax

	Current Quarter	Current Period
Operating profit is arrived at after charging / (crediting):	rging / (crediting): RM'000	
Depreciation and amortization	5,684	22,863
(Write-back)/Provision for receivables	(3,013)	(2,205)
(Write-back)/Provision for inventories	(286)	914
Net foreign exchange loss/(gain)	(15)	1,100
Interest expense	3,834	20,346
Interest income	(2,206)	(5,991)

Other than the above, there were no impairment of assets and gain or loss on derivatives for the current quarter and the current period under review.



# CHEMICAL COMPANY OF MALAYSIA BERHAD (5136-T) (Incorporated in Malaysia) For the Period Ended 31 December 2018

### **B7)** Status of Corporate Proposals

On 7 September 2018, the Company entered into a Sale and Purchase Agreement with Rock Link Sdn Bhd in relation to proposed disposal of a piece of land held under H.S.(D) 75345, PT 6055, in Mukim of Labu, District of Seremban, Negeri Sembilan for a purchase consideration of RM21.5 million.

On 13 December 2018, the Company obtained the Consent to Transfer from the State Authority and subsequently on 18 December 2018, the Company has also obtained approval from the Economic Planning Unit (EPU) on the sale and transfer of the said Property to the Purchaser. As such, all Conditions Precedent as stated in the Sale and Purchase Agreement dated 7 September 2018 have been fulfilled on 21 December 2018. The disposal is expected to be completed within 3 months upon full settlement by the purchaser.

Save for as disclosed above, there are no other corporate proposals that have been announced by the Company but not yet completed as at the date of this report.

#### **B8)** Group Borrowings and Debt Securities

	31 December	31 December	
	2018	2017	
	RM'000	RM'000	
Short term borrowings			
Unsecured			
Ringgit Malaysia denominated	41,695	359,388	
Long term borrowings			
Unsecured			
Ringgit Malaysia denominated	152,107	108,750	
	193,802	468,138	

## **B9)** Material Litigation

There were no material litigations as at the end of the period under review.

## B10) Dividend

On 14 December 2018, the Board of Directors had approved a second single-tier interim dividend of 4.00 sen (2017: nil) per share for the financial year ended 31 December 2018, based on the issued share capital of 167.7 million shares amounting to approximately RM6.7 million, which was paid on 31 January 2019.

The Board of Directors recommends a final single tier dividend of 2.0 sen per share (2017: nil) for the financial year ended 31 December 2018, based on issued share capital of 167.7 million shares amounting to approximately RM3.4 million. The final dividend is subject to shareholders' approval at the forthcoming 57<sup>th</sup> Annual General Meeting of the Company. The entitlement date in respect of the final single tier dividend will be on 31 May 2019 and the payment will be made on 14 June 2019.



(Incorporated in Malaysia)

For the Period Ended 31 December 2018

## **B11)** Earnings per Share

	Individual Quarter		Cumulative Quarter	
	31 December	31 December	31 December	31 December
	2018	2017	2018	2017
	RM'000	RM'000	RM'000	RM'000
Basic Earnings Per Share:-				
Profit after tax and minority shareholders' interests (RM'000)				
- from continuing operations	8,634	(6,939)	25,706	(5,239)
- from discontinued operations	-	8,131	-	31,158
	8,634	1,192	25,706	25,919
Weighted average number of ordinary		_		
shares ('000) at ending of the quarter/year	167,696	462,615	167,696	462,615
Basic earnings per share (sen)				
- from continuing operations	5.15	(1.50)	15.33	(1.13)
- from discontinued operations	-	1.76	-	6.74
	5.15	0.26	15.33	5.61

There is no dilution to the earnings per ordinary share as there are no potentially dilutive ordinary shares.

### **B12**) Derivative Financial Instruments

As at the end of the current period, there were no outstanding derivative financial instruments in the Group.

## **B13**) Gains and Losses Arising from Fair Value Changes of Financial Liabilities

There were no material gains or losses from changes on the fair values of financial liabilities for the current period under review.

## **B14)** Authorisation for Issue

The interim financial report was authorised for issue by the Board of Directors in accordance with a resolution of the directors on 22 February 2019.

By Order of the Board

NOOR AZWAH SAMSUDIN (LS0006071) Company Secretary 22 February 2019